Anti‑CD20 and Pregnancy: Encouraging MS Results

Credibility

Interest

Share:2 min read

Key Takeaway

In this Italian registry study, MS patients who got anti‑CD20 drugs before or very early in pregnancy generally kept good disease control and had birth outcomes similar to the general population.

What They Found

Researchers looked at 153 pregnancies in women with MS who had taken anti‑CD20 drugs (rituximab, ocrelizumab, or ofatumumab) shortly before or during pregnancy. About 80% of the pregnancies ended in a live birth and about 13% ended in miscarriage, numbers similar to what we see in the general population. Miscarriage was more common in the group whose last drug dose was very close to conception, but the overall rate was similar to national averages. MS relapse rates stayed about the same during pregnancy; after pregnancy relapses were slightly higher only in the group who had stopped treatment earlier. There were very few serious newborn infections or major birth defects reported, and disease activity on brain imaging tended to stay stable or improve after pregnancy in patients who had recent anti‑CD20 exposure.

Who Should Care and Why

Women with MS who are thinking about getting pregnant may care because this study suggests recent anti‑CD20 treatment can keep MS under control during and after pregnancy, which can make daily life easier and reduce relapses. Caregivers and partners may find comfort in knowing most pregnancies ended well and serious newborn problems were rare, which helps with planning and reducing anxiety. Healthcare providers can use this information when discussing timing of treatment and pregnancy, much like planning the best time to stop or keep a medication before a big event. Those who had their last drug dose very close to conception should be aware miscarriage rates were higher in that group, so extra monitoring might be advised. People who worry about infections or birth defects can be reassured that this study found few such problems, though careful follow up is still important.

Important Considerations

This study looked at real‑world results but it is not a randomized trial, so other factors might have influenced outcomes. The number of pregnancies is modest and most were with ocrelizumab, so results may not apply equally to all anti‑CD20 drugs or every patient. More and larger studies are needed to be certain about rare risks and to guide exact timing of medication around pregnancy.

AI-generated summary — for informational purposes only, not medical advice

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News

Anti‑CD20 and Pregnancy: Encouraging MS Results

Key Takeaway

What They Found

Who Should Care and Why

Important Considerations

You May Also Like

Understanding MS Research